Egyptian study pits two liver cancer drug combos Head-to-Head
Knowledge-focused
Ongoing
This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …
Sponsor: Sohag Oncology Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC